ClearUP
Commercial- Indications
- Sinus pain, Nasal congestion, Allergic rhinitis
Company intelligence / Profile preview
Entolimod™ has completed Phase III trials in acute radiation syndrome under the FDA animal efficacy rule. No further human trials required; focus now on manufacturing validation and regulatory submission. The company’s non-invasive vagus nerve stimulation technology has shown promising results in modulating autonomic function and inflammation in early studies. ClearUP®, their first product—a handheld neuromodulation device—is FDA approved and commercially available for sinus pain/congestion relief.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tivic Health.